Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Recurrence 4Ovarian Neoplasms 4Glioblastoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Lymphangioleiomyomatosis 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophagogastric Adenocarcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × nintedanib × Clear all
NCT02399215 2023-12-26

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 2 Completed
32 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡